Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage ...
TipRanks on MSN
Cybin to Release Q2 Financial Results and Business Update
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals ...
Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage ...
Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery ...
The latest announcement is out from Cybin ( (TSE:CYBN) ).
Cybin is a breakthrough Phase 3 clinical-stage neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the ...
Investing.com -- Cybin Inc. (NYSE American:CYBN) stock surged 18% after the clinical stage neuropsychiatry company announced a $175 million registered direct offering of common shares and pre-funded ...
Priority Technology Holdings, Inc. ("Priority" or the "Company"), the payments and banking solution that streamlines collecting, storing, lending, and sending money to unlock revenue opportunities, ...
Investing.com - Cantor Fitzgerald has reiterated its Overweight rating on Cybin Inc. (NYSE:CYBN), a $155 million market cap company developing psychedelic-based therapeutics for mental health ...
NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cybin Inc. ("Cybin" or the "Company") (NYSE: CYBN). Such investors are advised to contact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback